The Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) …
https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know
WEBJun 13, 2022 · The AstraZeneca vaccine has an efficacy of 72% against symptomatic SARS-CoV-2 infection, as shown by the primary analysis of data irrespective of interdose interval from trial participants who received 2 standard doses with an interval varying from about 4 to 12 weeks.
DA: 43 PA: 4 MOZ Rank: 37